Le medicament du mois. Valdecoxib (Bextra)

Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use; Arthritis, Rheumatoid/drug therapy; Cyclooxygenase Inhibitors/administration & dosage/therapeutic use; Dysmenorrhea/drug therapy; Enzyme Inhibitors/administration & dosage/therapeutic use; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Isoxazoles/administration & dosage/therapeutic use; Osteoarthritis/drug therapy; Pain, Postoperative/drug therapy; Prodrugs; Sulfonamides/administration & dosage/therapeutic use

Abstract :

[en] Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic treatment of osteoarthritis or rheumatoid arthritis (10 to 20 mg once a day) and for the treatment of primary dysmenorrhea (40 mg once a day). Valdecoxib is as efficacious as conventional non-COX-2 selective NSAIDs, but offers the advantage of a much better gastrointestinal tolerance. Valdecoxib has a prodrug that can be administered intravenously or intramuscularly (parecoxib, Dynastat) and has been developed for the short-term treatment of postsurgical pain.

Disciplines :

Rheumatology
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Malaise, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie

Language :

French

Title :

Le medicament du mois. Valdecoxib (Bextra)

Alternative titles :

[en] Valdecoxib (Bextra)

Publication date :

2004

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

251-254

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 08 May 2009

Statistics

Number of views

368 (4 by ULiège)

Number of downloads

212 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Malaise M.- Les anti-inflammatoires non stéroïdiens. Rev Med Liège, 1996, 51, 123-125.
Scheen AJ.- A propos du mécanisme d'action des antiinflammatoires. Rev Med Liège, 1996, 51, 610-611.
Vane JR, Bakhle YS, Botting RM.- Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol, 1998, 38, 97-120.
Scheen AJ.- Le rofécoxib (Vioxx®). Rey Med Liège, 2000, 55, 751-753.
Scheen AJ.- Le célécoxib (Celebrex®). Rey Med Liège, 2001, 56, 53-55.
Samad TA, Moore KA, Sapirstein A, et al.- Interleukin-1b mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature, 2001, 410, 471-475.
Ormrod D, Wellington K, Wagstaff AJ.- Valdecoxib. Drugs, 2002, 62, 2059-2071.
Fricke J, Varkalis J, Zwillich S, et al.- Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther, 2002, 9, 89-97.
Koppert W, Wehrfritz A, Körber N, et al.- The cyclooxygenase isoenzyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain, 2004, 108, 148-153.
Cheer SM, Goa KL.- Parecoxib (parecoxib sodium). Drugs, 2001, 61, 1133-1141.
Makarowski W, Zhao WW, Bevirt T, et al.- Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomised, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage, 2002, 10, 290-296.
Bensen W, Weaver A, Espinoza L, et al.- Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomised, controlled comparison with placebo and naproxen. Rheumatology, 2002, 41, 1008-1016.
Sikes DH, Agrawal N, Zaho WW, et al.- Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol, 2002, 14, 1101-1111.
Leese PT, Recker D, Kruss ME.- Valdecoxib does not impair platelet function. Am J Emerg Med, 2002, 20, 275-281.
von Scheele B, Pena B, Wong J, et al.- Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. Rheumatology, 2003, 42 (Suppl. 3), iii53-iii59.